Related Experiment Video
Updated: Aug 15, 2026
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line
Jacob Bornstein1, Shlomi Sagi, Amer Haj
1Department of Obstetrics and Gynecology, Western Galilee Hospital, PO Box 21, Nahariya 22100, and Molecular Genetics Laboratory, Technion-Israel Institute of Technology, Haifa, Israel. mdjacob@tx.technion.ac.il
Objective:
To determine whether Arsenic Trioxide may be an effective treatment of human ovarian carcinoma, we examined if it induced apoptosis in human ovarian cancer cell line.
Methods:
The human ovarian cell line SKOV3 was exposed to different concentrations of As2O3: 0 (control), 0.1 microM, 1 microM, 5 microM and 10 microM. The effect on cells proliferation and apoptotic parameters was examined.
Results:
The most effective inhibitory Arsenic Trioxide concentrations were 5 microM and 10 microM, causing growth inhibition of 79% and 83%, respectively. The maximum inhibitory effect of Arsenic Trioxide on cellular proliferation was seen after 48 h. No morphological or molecular features of apoptosis have been observed. At the same time, there were no typical changes of cellular necrosis.
Conclusions:
The exact mechanism by which Arsenic Trioxide inhibits the growth of ovarian cancer cells is probably not by apoptosis. However, since As2O3 has been shown to inhibit ovarian cancer cellular growth, it should be further elucidated as a possible chemotherapeutic agent of ovarian cancer.
Insights
Arsenic Trioxide effectively inhibited ovarian cancer cell growth at higher concentrations. However, the mechanism of action does not appear to involve apoptosis, suggesting further research is needed for its potential as a chemotherapy agent.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian carcinoma is a significant cause of cancer-related mortality in women.
- Investigating novel chemotherapeutic agents is crucial for improving treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of Arsenic Trioxide (As2O3) in inhibiting human ovarian cancer cell proliferation.
- To determine if As2O3 induces apoptosis in the SKOV3 ovarian cancer cell line.
Main Methods:
- Human ovarian cancer cells (SKOV3) were treated with varying concentrations of Arsenic Trioxide (0-10 microM).
- Cell proliferation and apoptotic markers were assessed after treatment.
Main Results:
- Arsenic Trioxide demonstrated significant inhibition of ovarian cancer cell proliferation at 5 microM (79%) and 10 microM (83%).
- Maximum inhibition was observed at 48 hours.
- No evidence of apoptosis or necrosis was detected at the cellular or molecular level.
Conclusions:
- Arsenic Trioxide inhibits ovarian cancer cell growth through a mechanism independent of apoptosis.
- Further investigation is warranted to explore As2O3 as a potential chemotherapeutic agent for ovarian cancer.
